Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $2.8 billion.

  • Ptc Therapeutics' Total Non-Current Liabilities fell 270.33% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 270.33%. This contributed to the annual value of $2.8 billion for FY2024, which is 387.3% up from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Total Non-Current Liabilities is $2.8 billion, which was down 270.33% from $2.8 billion recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Total Non-Current Liabilities registered a high of $2.9 billion during Q2 2024, and its lowest value of $1.6 billion during Q1 2021.
  • In the last 5 years, Ptc Therapeutics' Total Non-Current Liabilities had a median value of $1.9 billion in 2023 and averaged $2.2 billion.
  • As far as peak fluctuations go, Ptc Therapeutics' Total Non-Current Liabilities surged by 13934.6% in 2021, and later tumbled by 270.33% in 2025.
  • Ptc Therapeutics' Total Non-Current Liabilities (Quarter) stood at $1.7 billion in 2021, then grew by 11.32% to $1.9 billion in 2022, then skyrocketed by 41.79% to $2.7 billion in 2023, then grew by 3.87% to $2.8 billion in 2024, then increased by 0.55% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q3 2025, $2.8 billion for Q2 2025, and $2.8 billion during Q1 2025.